Trials / Completed
CompletedNCT00927134
Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) in Children
Phase I/II Gene Therapy Study for X-linked Chronic Granulomatous Disease in Children
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- University of Zurich · Academic / Other
- Sex
- Male
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to evaluate the side effects and risks after infusion of retroviral gene corrected autologous CD34+ cells of the peripheral blood of chemotherapy conditioned (busulphan) children with chronic granulomatous disease (CGD). Also gene corrected and functional active granulocytes in the peripheral blood and the engraftment in the bone marrow of the patients will be monitored an documented.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | retroviral SF71-gp91phox transduced CD34+ cells | autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2010-12-01
- Completion
- 2011-09-01
- First posted
- 2009-06-24
- Last updated
- 2011-09-27
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00927134. Inclusion in this directory is not an endorsement.